ClinicalTrials.gg
Status unknownNCT03282110Updated Nov 7, 2017

Comprehensive Acupuncture for Depressive Disorder With Comorbid Psychogenic Pain

An Early Phase 1 interventional study of ta-VNS and Electro-acupuncture in Depression; Psychoneurotic and Pain, sponsored by China Academy of Chinese Medical Sciences. Status unknown. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-11-07.

Sponsored by China Academy of Chinese Medical Sciences · Early Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Experimental and clinical studies have indicated that acupuncture has a good effect for depression and comorbid pain. The purpose of this research is to compare the effect of comprehensive electro-acupuncture therapy and western medicine citalopram for for depressive disorder with comorbid psychogenic pain. This research is a assessor blinded, randomized controlled trials. 60 patients will be randomly divided into comprehensive electro-acupuncture group and western medicine citalopram for 8 weeks treatment and the therapeutic effect is done at the end of 1,2,4,6,8 week.

02

Conditions studied

  • Depression; Psychoneurotic
  • Pain
03

In context

Depression

8,605 studies on the registry are indexed under Depression; 1,735 are open to participants now.

This study's planned enrollment of 60 is below the median of 81 across 7,083 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

China Academy of Chinese Medical Sciences is the lead sponsor of 62 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Conform with the diagnostic criteria of depression according to (DSM-5TM)
  • Age from 18 to 50 year-old
  • Patients with the first onset depression
  • Patients with mild-to-moderate depression scored 12-30 by Montgomery scale
  • Patients with one psychogenic pain at least, and the degree of VAS is 3 or more
  • Volunteer participants willing to cooperate and obeying the treatment

Exclusion criteria

Exclusion Criteria:

  • Pregnant woman
  • Patients with severe primary diseases and acute diseases of heart, brain, liver, kidney and hematopoietic systems and infectious disease, malignant tumor
  • Patients who can't stop taking drugs according to the requirement in the treatment period
  • Patients with a history of schizophrenia and other mental disorders
  • Patients with cognitive impairment or personality disorders
  • Patients have serious suicide idea or suicidal behavior
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    ta-VNS & Electro-acupuncture

    1. Device:ta-VNS(transcutaneous vagus nerve stimulation):2 times per day,5 consecutive days per week for two months 2. Other:Electro-acupuncture:3 times per week, once every other day for two months

    Device: ta-VNS · Other: Electro-acupuncture

  • Active comparator
    Citalopram

    citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days;40mg for the left days within two months

    Drug: Citalopram

Interventions

  • Deviceta-VNS

    The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.

    Also known as: transcutaneous vagus nerve stimulation

  • OtherElectro-acupuncture

    one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.

  • Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.

    Also known as: brand name:Cipramil, SFDA J20130028

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale Change

    Measure the severity of depressive episodes in patients with mood disorders, It contents ten items, and each item is scored 0-6.(0=no depression,6=depression as bad as can be), yielding a total between 0 and 60.

    Time frame: Baseline and 1 week,baseline and 2 weeks,baseline and 4 weeks,baseline and 6 weeks,baseline and 8 weeks

Secondary outcomes

  1. SF-McGill Pain Questionnaire

    Measure pain in 3 ways:1)pain rating indexes: pain intensity from feeling and emotional aspects, it includes fifteen items and each item is scored 0-3(0=no pain 3=severe) 2)present pain intensity, scored 0-5(0=no pain, 5=intense pain) 3)VAS: visual analog scale

    Time frame: Baseline and 1 week,baseline and 2 weeks,baseline and 4 weeks,baseline and 6 weeks,baseline and 8 weeks

  2. SF-36 Health Survey Questionnaire

    Measure the self-reported living quality.It has eight sections:the physiological function, physiological function, the body pain, general health, energy, social function, emotional function and mental health.It consists of eight scaled scores, which are the weighted sums of the questions in their section.

    Time frame: Baseline and 4 weeks, baseline and 8 weeks

  3. Pittsburgh Sleep Quality Index

    A self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating seven components that produce one global score

    Time frame: Baseline and 1 week,baseline and 2 weeks,baseline and 4 weeks,baseline and 6 weeks,baseline and 8 weeks

  4. Hamilton Anxiety Rating Scale(HAMA)

    A psychological questionnaire used by clinicians to rate the severity of a patient's anxiety.Each of the 14 items contains some symptoms, and each group of symptoms is rated on a scale of zero to four, with four being the most severe.

    Time frame: Baseline and 1 week,baseline and 2 weeks,baseline and 4 weeks,baseline and 6 weeks,baseline and 8 weeks

Other outcomes

  1. Salivary cortisol levels

    Serum cortisol levels positively correlated with the severity of depression, so that the saliva should be collected before and after treatment. Acquisition time of saliva: 7:30~8:30 am and 3:00-4:00 p.m

    Time frame: baseline and 8 weeks

  2. Physiological indexes

    Including blood pressure, ECG, respiration, pulse check, blood routine, blood biochemistry, urine analysis to see if there is any change during treatment

    Time frame: baseline and 8 weeks

  3. Adverse events that are related to treatment

    Measure the incidence of adverse events of acupuncture such as fainting during acupuncture treatment.

    Time frame: baseline and 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2017; primary completion for Jun 2018, 7 months later.

Of 82 non-industry phase 1 interventional studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 61. This study's planned 7 months is below that.

Counting every sponsor, half of 102 studies reached it within 27 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2017
First posted
Sep 13, 2017
StartEst.
Nov 30, 2017
Primary completionEst.
Jun 30, 2018
CompletionEst.
Jun 30, 2019
Last update
Nov 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03282110
Lead sponsor
China Academy of Chinese Medical Sciences
Responsible party
Peijing Rong (The deputy director of Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, China Academy of Chinese Medical Sciences) — Principal investigator
First posted
Sep 13, 2017
Start date
Nov 30, 2017 (estimated)
Primary completion
Jun 30, 2018 (estimated)
Completion
Jun 30, 2019 (estimated)
Last update
Nov 7, 2017

Study contacts

Peijing Rong, Dotor
Contact
drrongpj@163.com
01064089301
Zhangjin Zhang, Dotor
Contact
zhangzj@hku.hk
+86 18307556273
Peijing Rong, Dotor
study director · Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences
Zhangjing Zhang, Dotor
study director · The School of Chinese Medicine, The University of Hong Kong

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion